1. Introduction {#sec1}
===============

Lung cancer is a common cause of mortality for both men and women \[[@B1]\]. Despite advances in treatment, the five-year overall survival (OS) rate is only 16.3% \[[@B2]\]. In the majority of cases, \>80% of lung cancer diagnoses are of the non-small cell lung cancer (NSCLC) type \[[@B3]\], and there are more and more evidences to associate low level of pretreatment hemoglobin with poor survival in patients with NSCLC \[[@B4]--[@B6]\]; however, there was no report to associate pretreatment hemoglobin level with the prognosis of adenocarcinoma, a major subtype of NSCLC.

In the present study, we aim to investigate the prognostic value of pretreatment hemoglobin levels for the survival of patients with LA.

2. Materials and Methods {#sec2}
========================

From May 2010 to June 2017, 736 patients with lung cancer were diagnosed at the Henan University Huaihe Hospital (Henan, China). The clinical data were retrospectively collected. After excluding 430 ineligible subjects, a total of 306 patients with LA (152 men and 154 women) were selected as subjects for the present study. All cases of LA were pathologically confirmed. The survival period for each subject was defined as the number of days from the date of diagnosis to the date of mortality. Person-years were calculated for each subject. Patients were included in this study if they had a verified diagnosis of LA, regardless of whether they had received prior lung lobectomy, chemotherapy, or radiotherapy treatments.

The clinical stage was assigned on the basis of the 8th Edition of the TNM Classification for Lung Cancer \[[@B7]\]. Anonymous data regarding age, sex, histological cancer type, TNM stage, Karnofsky performance status (KPS) \[[@B8]\], lung lobectomy, chemotherapy, radiotherapy, smoking status, alcohol consumption, family history, diagnosis date, hemoglobin levels, and date of mortality were obtained retrospectively from the patients\' medical records, local death registration departments and telephone follow-ups. The study was approved by the Medical Ethics Committee of the Henan University Huaihe Hospital.

The pretreatment hemoglobin levels of the patients were obtained. The LPHb level was defined as \<120 g/l of hemoglobin in men, and as \<110 g/l in women. All patients were dichotomized into an LPHb group (*n*=53) and a normal pretreatment hemoglobin (NPHb) group (*n*=253). Comparisons of clinical characteristics between the LPHb and NPHb groups were conducted using the chi-squared (*χ* ^2^) test. For univariate Cox proportional hazards regression, age, sex, TNM stages, KPS scores, lung lobectomy status, chemotherapy, radiotherapy, smoking status, alcohol consumption, family history, and hemoglobin levels were dichotomized into a favorable group and an unfavorable group. Hazards ratios (HRs) and 95% confidence intervals (CIs) were calculated to estimate associations between the observed factors and case fatality rate (CFR) of patients with LA. A subsequent multivariate analysis using the Cox proportional hazards model estimated the prognostic influence of age, sex, TNM stage, KPS, lung lobectomy, chemotherapy, radiotherapy, and hemoglobin levels on the CFR of patients with LA.

Survival curves were generated using the Kaplan--Meier analysis method, and the log-rank test was used to examine differences in survival between the various hemoglobin groups. All statistical analyses were performed using Stata software version 13 (Stata Corporation, College Station, TX, USA). *P* \< 0.05 was considered statistically significant for all analyses.

3. Results {#sec3}
==========

As shown in [Table 1](#tab1){ref-type="table"}, of the 306 patients, 118 (38.6%) were smokers and 38 (12.4%) were alcohol drinkers. In total, 172 (56.2%) patients were at TNM stage IV and 134 (43.8%) were at stage I--III including those unidentified.

Statistical analysis showed that there were significant differences in hemoglobin levels between men and women (*P*=0.020), KPS scores (*P*=0.003), smokers and non-smokers (*P*=0.008), alcohol drinkers and non-drinkers (*P*=0.043), and survival time (*P*=0.005).

The univariate Cox proportional hazards regression analysis showed that patients who were older than 65 years of age (HR = 1.37 and 95% CI = 1.05--1.78), were at TNM stage IV (HR = 2.16 and 95% CI = 1.65--2.82), had KPS scores \< 80 (HR = 1.88 and 95% CI = 1.45--2.43), had not received lung lobectomy (HR = 2.78 and 95% CI = 2.02--3.83), had not received chemotherapy (HR = 1.48 and 95% CI = 1.14--1.91), drank alcohol (HR = 1.69 and 95% CI = 1.17--2.45), or had LPHb levels (HR = 1.61 and 95% CI = 1.16--2.24) had a significantly increased CFR. However, sex, radiotherapy, smoking status, and family history did not have any significant associations with the CFR of patients with LA ([Table 2](#tab2){ref-type="table"}).

The multivariate Cox proportional hazards regression analysis showed that LPHb levels were independently associated with an increased CFR (HR = 1.48 and 95% CI = 1.06--2.08). In addition, lung lobectomy (HR = 2.01, 95% CI = 1.32--3.05), chemotherapy (HR = 1.47 and 95% CI = 1.10--1.95), and alcohol drinking (HR = 1.60, 95% CI = 1.06--2.41) were also independent and favorable prognostic factors ([Table 3](#tab3){ref-type="table"}).

Kaplan--Meier survival curve estimations showed that patients with LPHb had a poorer OS than did patients with NPHb levels (log-rank test, *χ* ^2^ = 8.28, and *P*=0.004, [Figure 1(a)](#fig1){ref-type="fig"}). When the patients were subdivided by lung lobectomy, the LPHb patients had a poorer OS than the NPHb patients in the no-lung lobectomy group (log-rank test, *χ* ^2^ = 7.69, and *P*=0.006, [Figure 1(b)](#fig1){ref-type="fig"}), a difference not observed in the lung lobectomy group (log-rank test, *χ* ^2^ = 0.13, and *P*=0.7154, [Figure 1(b)](#fig1){ref-type="fig"}).

When we subdivided the patients according to chemotherapy, the LPHb group had a poorer OS than the NPHb patients in the no-chemotherapy group (log-rank test, *χ* ^2^ = 12.00, and *P* \< 0.001, [Figure 1(c)](#fig1){ref-type="fig"}) but not in the chemotherapy group (log-rank test, *χ* ^2^ = 0.63, and *P*=0.427, [Figure 1(c)](#fig1){ref-type="fig"}). The subdivision of patients according to alcohol drinking also showed that the LPHb patients had a poorer OS than the NPHb patients among alcohol drinkers (log-rank test, *χ* ^2^ = 12.14, and *P* \< 0.001, [Figure 1(d)](#fig1){ref-type="fig"}), but not among alcohol non-drinkers (log-rank test, *χ* ^2^ = 3.22, and *P*=0.073, [Figure 1(d)](#fig1){ref-type="fig"}).

4. Discussion {#sec4}
=============

Our data suggest that pretreatment hemoglobin level, measured at the time of diagnosis, may be an independent predictor for the prognosis of patients with LA, as is the case in the no-lung lobectomy and/or no-chemotherapy patients. To the best of our knowledge, this is the first report that associated pretreatment hemoglobin levels with the prognosis of patients with LA.

Low hemoglobin is common in oncological diseases, such as lung \[[@B9], [@B10]\], breast \[[@B10]\], gastric \[[@B11]\], and ovarian cancer \[[@B12]\]. There is evidence for a correlation between hemoglobin levels and the prognosis of patients with NSCLC. But precise underlying mechanisms are not fully understood. Tumor cells secrete a number of soluble molecules, including interleukin-6 (IL-6) and tumor necrosis factor-*α* (TNF-*α*). These molecules could decrease hemoglobin by changing the hematopoietic environment \[[@B13], [@B14]\], suppressing erythropoiesis and erythropoietin (EPO) \[[@B15]\], and impairing the EPO response in erythroid progenitor cells \[[@B16]\]. Moreover, in patients with bone metastasis, bone marrow involvement may lead to bone morrow failure, which may then cause low-hemoglobin levels \[[@B17]\] and subsequently lead to hypoxia, which could induce genomic changes and enhance the development of malignancy \[[@B18]\]. Hypoxia may also boost tumor angiogenesis and accelerate metastasis \[[@B19]\]. Moreover, hypoxia may enhance tumor cell resistance to chemotherapy and radiotherapy through the development of multidrug resistance \[[@B20]\].

For associations of hemoglobin level with lung adenocarcinoma, we did not find previous studies and know little about the mechanisms beneath the surface of water. There was no difference in OS for lung lobectomy group based on Hb, and similar result was found in the chemotherapy group. This is not in line with the previous study of LPHb in patients with non-small cell lung cancer \[[@B21]\]. In a previous study of lung adenocarcinoma patients with LPHb, because of lack of data, we could not analyze the reason. In the present study, about half of the patients abandoned clinical treatment (Supplementary [Table 1](#supplementary-material-1){ref-type="supplementary-material"}), and their OS was significantly shorter than those who had received clinical treatments (Supplementary [Table 2](#supplementary-material-1){ref-type="supplementary-material"}). We thus suggest that it is difficult to exclude possibilities that it is the clinical treatment that had obscured associations of pretreatment hemoglobin with the final OS. Cigarette smoking was not associated with the OS of LA. This is inconsistent with other studies \[[@B22], [@B23]\]. We think this maybe related to the fact that we only consider cigarette smoking, without considering the detailed smoking index. But alcohol drinking was significantly and independently associated with the OS of LA, which might be supported by previous studies \[[@B24], [@B25]\]. Those who had LPHb and drank alcohol had a worst OS.

A major strength of our study was the inclusion of a large number of patients with LA, all with a complete set of clinical data, including the pretreatment hemoglobin levels, the complete survival period, records of multiple treatments, and the family history and lifestyle details, including smoking status and alcohol consumption; this enabled us to investigate the prognostic value of pretreatment hemoglobin levels with decreased sample bias and offset heterogeneity. However, there are also limitations to our study. First, our study was retrospective, and the information on posttreatment recurrence was insufficient. Second, we did not follow alterations of hemoglobin level after pretreatment measurement during clinical treatment and afterwards.

Both lung lobectomy and chemotherapy treatments were associated with the prognosis of patients with LA. However, neither significantly affected the prognostic value of the pretreatment hemoglobin levels in the present study. As for associations of alcohol drinking with the prognosis of LA, we suggest further investigations to confirm the finding.

5. Conclusion {#sec5}
=============

Our study suggests that low pretreatment hemoglobin level could be an independent biomarker for poor prognosis in patients with LA. In future clinical studies, the hemoglobin levels should be considered during the work-up of patients with LA in prospective trials, in order to confirm its prognostic significance.
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Table 1: distribution of patients with lung adenocarcinoma among TNM stages, chemotherapy, and lung lobectomy. Table 2: treatment modality and survivals (months) of patients with lung adenocarcinoma in Henan, China.

###### 

Click here for additional data file.

![Cumulative survival proportion of patients with LA according to their pretreatment hemoglobin levels. Normal pretreatment hemoglobin (NPHb): men 120--160 g/l, women 110--150 g/l; low pretreatment hemoglobin (LPHb): men \< 120 g/l and women ≤ 110 g/l). (a) Overall survival (OS) of NPHb and LPHb patients with LA (log-rank test, *χ* ^2^ = 8.28, and *P*=0.004). (b) LPHb patients had a poorer OS than NPHb patients in the no-lung lobectomy group (log-rank test, *χ* ^2^ = 7.69, *P*=0.006) but not among the lung lobectomy group (log-rank test, *χ* ^2^ = 0.13, *P*=0.7154). (c) The LPHb group had a poorer OS than NPHb patients in the no-chemotherapy group (log-rank test, *χ* ^2^ = 12.00, and *P* \< 0.001) but not among the chemotherapy group (log-rank test, *χ* ^2^ = 0.63, and *P*=0.427). (d) LPHb patients had a poorer OS than NPHb patients among alcohol drinkers (log-rank test, *χ* ^2^ = 12.14, and *P* \< 0.001), but not among alcohol non-drinkers (log-rank test, *χ* ^2^ = 3.22, and *P*=0.073).](CRJ2018-6328127.001){#fig1}

###### 

Pretreatment hemoglobin levels among clinicopathological and lifestyle factors in lung adenocarcinoma patients, Henan, China, 2017.

                             NPHb^1^   LPHb^2^   *P* value^3^
  -------------------------- --------- --------- --------------
  Age (years)                                     
   \<65                      147       24        0.087
   ≥65                       106       29         
                                                 
  Sex                                             
   Man                       118       34        0.020
   Women                     135       19         
                                                 
  TNM^4^ stage                                    
   I--III                    115       19        0.200
   IV                        138       34         
                                                 
  KPS^5^                                          
   ≥80                       151       20        0.003
   \<102                     33        60         
                                                 
  Lung lobectomy                                  
   Yes                       77        11        0.157
   No                        176       42         
                                                 
  Chemotherapy                                    
   Yes                       131       23        0.267
   No                        122       30         
                                                 
  Radiotherapy                                    
   Yes                       36        5         0.351
   No                        217       48         
                                                 
  Cigarette smoking                               
   No                        164       24        0.008
   Yes                       89        29         
                                                 
  Alcohol drinking                                
   No                        226       42        0.043
   Yes                       27        11         
                                                 
  Family history of cancer                        
   No                        234       50        0.636
   Yes                       19        3          
                                                 
  Survival year                                   
   ≥1 year                   100       32        0.005
   \<1 year                  153       21         

^1^NPHb (normal pretreatment hemoglobin): men 120--160 g/l and women 110--150 g/l; ^2^LPHb (low pretreatment hemoglobin): men \< 120 g/l and women ≤ 110 g/l). ^3^Chi-squared (*χ* ^2^) test. ^4^TNM: tumor-node-metastasis. ^5^KPS: Karnofsky performance status.

###### 

Univariate analysis of prognostic factors for patients with lung adenocarcinoma in Henan, China, 2017.

  Factor           Person-years   Cases   Case fatality rate (%)   HR^1^   95% CI^2^    *P* value
  ---------------- -------------- ------- ------------------------ ------- ------------ -----------
  Total            421.3          233     55.3                                           
  Age                                                                                    
   \<65            263.7          129     48.9                     1.00                  
   ≥65             157.7          104     65.9                     1.37    1.05--1.78   0.019
                                                                                        
  Sex                                                                                    
   Man             201.8          120     59.5                     1.00                  
   Women           219.5          113     51.5                     0.87    0.67--1.12   0.280
                                                                                        
  TNM^3^ stage                                                                           
   I--III          228.9          85      37.1                     1.00                  
   IV              192.5          148     76.9                     2.16    1.65--2.82   \<0.001
                                                                                        
  KPS^4^ scores                                                                          
   ≥80             269.5          115     42.7                     1.00                  
   \<80            151.8          118     77.7                     1.88    1.45--2.43   \<0.001
                                                                                        
  Lung lobectomy                                                                         
   Yes             172.2          49      28.5                     1.00                  
   No              249.1          184     73.9                     2.78    2.02--3.83   \<0.001
                                                                                        
  Chemotherapy                                                                           
   Yes             248.4          117     47.1                     1.00                  
   No              173.0          116     67.1                     1.48    1.14--1.91   0.003
                                                                                        
  Radiotherapy                                                                           
   Yes             71.6           32      44.7                     1.00                  
   No              349.7          201     57.5                     1.33    0.92--1.94   0.132
                                                                                        
  Smoking                                                                                
   No              260.2          138     53.0                     1.00                  
   Yes             161.1          95      59.0                     1.09    0.84--1.42   0.500
                                                                                        
  Alcohol                                                                                
   No              382.9          200     52.2                     1.00                  
   Yes             38.5           33      85.7                     1.69    1.17--2.45   0.006
                                                                                        
  Family history                                                                         
   No              385.9          218     56.5                     1.00                  
   Yes             35.4           15      42.4                     0.73    0.43--1.24   0.248
                                                                                        
  Hemoglobin^5^                                                                          
   NPHb            367.1          189     51.5                     1.00                  
   LPHb            54.3           44      81.0                     1.61    1.16--2.24   0.004

^1^HR: hazard ratio by multivariate Cox proportional hazards regression. ^2^CI: confidence interval. ^3^TNM: tumor-node-metastasis. ^4^KPS: Karnofsky performance status. ^5^Hemoglobin: NPHb (normal pretreatment hemoglobin): men 120--160 g/l and women 110--150 g/l; LPHb (low pretreatment hemoglobin): men \< 120 g/l and women ≤ 110 g/l.

###### 

Multivariate analysis of prognostic factors for patients with lung adenocarcinoma in Henan, China, 2017.

  Factor             HR^1^   95% CI^2^    *P* value
  ------------------ ------- ------------ -----------
  Age                                      
   \<65              1.00                  
   ≥65               1.20    0.90--1.60   0.211
                                          
  Sex                                      
   Man               1.00                  
   Women             0.89    0.66--1.19   0.432
                                          
  TNM^3^ stage                             
   I--III            1.00                  
   IV                1.39    0.98--1.99   0.067
                                          
  KPS^4^ scores                            
   ≥80               1.00                  
   \<80              1.24    0.93--1.64   0.139
                                          
  Lung lobectomy                           
   Yes               1.00                  
   No                2.01    1.32--3.05   0.001
                                          
  Chemotherapy                             
   Yes               1.00                  
   No                1.47    1.10--1.95   0.008
                                          
  Radiotherapy                             
   Yes               1.00                  
   No                1.00    0.68--1.49   0.981
                                          
  Alcohol drinking                         
   No                1.00                  
   Yes               1.60    1.06--2.41   0.026
                                          
  Hemoglobin^5^                            
   NPHb              1.00                  
   LPHb              1.48    1.06--2.08   0.023

^1^HR: hazard ratio by multivariate Cox proportional hazards regression. ^2^CI: confidence interval. ^3^TNM: tumor-node-metastasis. ^4^KPS: Karnofsky performance status. ^5^Hemoglobin: NPHb (normal pretreatment hemoglobin): men 120--160 g/l and women 110--150 g/l; LPHb (low pretreatment hemoglobin): men \< 120 g/l and women ≤ 110 g/l.
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